Clemizole HCl + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dravet Syndrome
Conditions
Dravet Syndrome
Trial Timeline
Sep 15, 2020 → May 1, 2029
NCT ID
NCT04462770About Clemizole HCl + Placebo
Clemizole HCl + Placebo is a phase 3 stage product being developed by Harmony Biosciences for Dravet Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04462770. Target conditions include Dravet Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05066217 | Phase 3 | Recruiting |
| NCT04462770 | Phase 3 | Recruiting |
Competing Products
15 competing products in Dravet Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| ZX008 0.2 to 0.8 mg/kg/day + Cannabidiol | UCB | Phase 1 | 30 |
| fenfluramine | UCB | Approved | 82 |
| Fenfluramine Hydrochloride | UCB | Pre-clinical | 20 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| fenfluramine | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 74 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| Clobazam + Placebo | Lundbeck | Phase 3 | 74 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Approved | 82 |
| zorevunersen | Stoke Therapeutics | Phase 3 | 72 |
| STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses | Stoke Therapeutics | Phase 1/2 | 36 |
| zorevunersen (STK-001) | Stoke Therapeutics | Phase 2 | 47 |